Jump to main content
Jump to site search

Issue 7, 2019
Previous Article Next Article

Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics

Author affiliations

Abstract

Peptides and small protein scaffolds are gaining increasing interest as therapeutics. Similarly to full-length antibodies, they can bind a target with a high binding affinity and specificity while remaining small enough to diffuse into tissues. However, despite their numerous advantages, small biotherapeutics often suffer from a relatively short circulating half-life, thus requiring frequent applications that ultimately restrict their ease of use and user compliance. To overcome this limitation, a large variety of half-life extension strategies have been developed in the last decades. Linkage to ligands that non-covalently bind to albumin, the most abundant serum protein with a circulating half-life of ∼19 days in humans, represents one of the most successful approaches for the generation of long-lasting biotherapeutics with improved pharmacokinetic properties and superior efficacy in the clinic.

Graphical abstract: Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics

Back to tab navigation

Article information


Submitted
11 Jan 2019
Accepted
01 Jun 2019
First published
06 Jun 2019

Med. Chem. Commun., 2019,10, 1068-1081
Article type
Review Article

Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics

A. Zorzi, S. Linciano and A. Angelini, Med. Chem. Commun., 2019, 10, 1068
DOI: 10.1039/C9MD00018F

Search articles by author

Spotlight

Advertisements